Search

Your search keyword '"James R. Heath"' showing total 343 results

Search Constraints

Start Over You searched for: Author "James R. Heath" Remove constraint Author: "James R. Heath" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
343 results on '"James R. Heath"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer

3. Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

5. Stereochemical engineering yields a multifunctional peptide macrocycle inhibitor of Akt2 by fine-tuning macrocycle-cell membrane interactions

6. Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis

7. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

8. T cell receptor sequences are the dominant factor contributing to the phenotype of CD8+ T cells with specificities against immunogenic viral antigens

9. Effects of HLA single chain trimer design on peptide presentation and stability

10. Prediction of HLA genotypes from single-cell transcriptome data

11. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.

12. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1

13. Constraint-Based Reconstruction and Analyses of Metabolic Models: Open-Source Python Tools and Applications to Cancer

14. Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells

15. Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line

16. Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping

17. Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report

18. Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection

20. Microfluidic Single-Cell Proteomics Assay Chip: Lung Cancer Cell Line Case Study

21. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood

22. Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance.

23. Supplementary Figures 1 - 8 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

24. Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

25. Supplementary Methods, Figure Legends, Table 1 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

26. Supplementary Figure 5 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

27. Supplementary Figure Legend from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

28. Supplementary Figure 8 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

29. Data from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

30. Supplementary Figure 9 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

31. Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

32. Supplementary Figure 3 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

33. Supplementary Figure 6 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

34. Supplementary Figure 7 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

35. Supplementary Figure 4 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

36. Supplementary Figure 1 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

37. Supplementary Figure 1 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

38. Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

39. Supplementary Figure 6 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

40. Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

41. Supplementary Figure 5 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

42. Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

43. Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

44. Non-viral precision T cell receptor replacement for personalized cell therapy

45. A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.

46. Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcεRIγ expression

47. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

48. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation

49. Prediction of HLA genotypes from single-cell transcriptome data

50. Abstract 4876: A systems pharmacology approach to discover synergistic targeted therapy combinations

Catalog

Books, media, physical & digital resources